Compare ARVN & EGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | EGY |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 652.7M |
| IPO Year | 2018 | 1996 |
| Metric | ARVN | EGY |
|---|---|---|
| Price | $8.96 | $5.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 1 |
| Target Price | ★ $15.05 | $7.30 |
| AVG Volume (30 Days) | 854.3K | ★ 1.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.75% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | N/A |
| Revenue | $262,600,000.00 | ★ $359,272,000.00 |
| Revenue This Year | N/A | $8.78 |
| Revenue Next Year | N/A | $29.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.06 | $3.16 |
| 52 Week High | $14.22 | $6.72 |
| Indicator | ARVN | EGY |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 38.64 |
| Support Level | $7.35 | $5.53 |
| Resistance Level | $10.18 | $6.71 |
| Average True Range (ATR) | 0.51 | 0.21 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 23.34 | 5.72 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.